期刊
CANCERS
卷 13, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/cancers13194932
关键词
PDAC; tumor stroma; immune cells; endothelial cells; CAFs; myofibroblasts; microbiome; macrophages; personalized medicine
类别
资金
- Research and Training Group 2501 on Translational Evolutionary Research (RTG 2501 TransEvo, DFG)
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [413490537]
- Deutsche Krebshilf [AZ 70112935]
- DFG
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors commonly diagnosed at advanced stages, characterized by tumor heterogeneity at multiple levels. This tumor heterogeneity, along with the impact of the tumor microenvironment and altered microbiome of PDAC patients, plays diverse effects on the development, progression, and therapy responses of PDAC. Understanding and considering this multi-level heterogeneity is crucial for developing novel therapeutic concepts to potentially improve the situation of PDAC patients.
Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at advanced stages and most anti-cancer therapies have failed to substantially improve prognosis of PDAC patients. As a result, PDAC is still one of the deadliest tumors. Tumor heterogeneity, manifesting at multiple levels, provides a conclusive explanation for divergent survival times and therapy responses of PDAC patients. Besides tumor cell heterogeneity, PDAC is characterized by a pronounced inflammatory stroma comprising various non-neoplastic cells such as myofibroblasts, endothelial cells and different leukocyte populations which enrich in the tumor microenvironment (TME) during pancreatic tumorigenesis. Thus, the stromal compartment also displays a high temporal and spatial heterogeneity accounting for diverse effects on the development, progression and therapy responses of PDAC. Adding to this heterogeneity and the impact of the TME, the microbiome of PDAC patients is considerably altered. Understanding this multi-level heterogeneity and considering it for the development of novel therapeutic concepts might finally improve the dismal situation of PDAC patients. Here, we outline the current knowledge on PDAC cell heterogeneity focusing on different stromal cell populations and outline their impact on PDAC progression and therapy resistance. Based on this information, we propose some novel concepts for treatment of PDAC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据